EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 21 (2014) Parasite, 21 (2014) 55 Full HTML
Open Access
Review
Issue
Parasite
Volume 21, 2014
Article Number 55
Number of page(s) 4
DOI https://doi.org/10.1051/parasite/2014056
Published online 28 October 2014

© M.F. Heyworth, published by EDP Sciences, 2014

Licence Creative CommonsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Giardia intestinalis (synonyms: G. duodenalis, G. lamblia) is a protozoan parasite that colonises the small intestinal lumen of vertebrate hosts. In human subjects, G. intestinalis infections range in clinical severity from asymptomatic colonisation to a debilitating syndrome that includes chronic diarrhoea and malabsorption. The two-stage life cycle of Giardia species comprises the motile trophozoite, with eight flagella and a ventral adhesive disc by which it adheres to the luminal surface of intestinal epithelial cells (and thereby resists peristaltic expulsion from the host’s intestine), and the thick-walled cyst, which is excreted from the host. Previously uninfected hosts become infected by oral ingestion of Giardia cysts.

Giardia infections are increased in intensity and/or duration in human or non-human mammalian hosts with various forms of immunodeficiency, in comparison with their immunocompetent counterparts [9, 14, 20]. This situation indicates that host immunological responses limit the intensity and/or duration of these infections. The extant literature suggests that impaired production of anti-Giardia antibodies is the main reason why immunodeficiency states predispose to severe/prolonged Giardia infections [4]. From the 1980s onwards, it has been known that Giardia-infected human and non-human hosts generate serum and intestinal antibody responses against Giardia trophozoites [10, 28]. Anti-Giardia IgA is present in the intestinal lumen of Giardia-infected hosts and has also been detected in human milk [10, 32]. Colostrum from cows with G. intestinalis-infected calves contains anti-Giardia IgG [19]. Intraperitoneal or intraduodenal administration of anti-G. muris antibody leads to reduction in the number of intestinal G. muris trophozoites, in mice infected with this parasite [1, 3]. This result is consistent with a role for antibodies in clearing G. muris from the mouse intestinal lumen.

Giardia trophozoite antigens that are recognised by antibodies of Giardia-infected hosts include heterogeneous “variant-specific surface proteins” (VSPs), and non-variable (structurally conserved) proteins [21]. Of a repertoire of approximately 150 (or more) VSPs in Giardia intestinalis, only one VSP appears to be expressed on an individual Giardia trophozoite at any one time, other than during antigenic “switching” [17, 18]. It has been speculated that antigenic switching by Giardia trophozoites, whereby expression of one VSP changes to that of a different VSP, might be an immune evasion strategy (an adaptation by the parasite to the presence of host antibodies directed against whichever VSP is initially expressed by a population of trophozoites in the intestinal lumen) [17]. The observation that G. intestinalis trophozoites switch from the expression of one VSP to another in the absence of antibodies, during in vitro culture [18], does not rule out the possibility that antibodies might select against the persistence of initially expressed VSP(s) in the host. The biological role, if any, of VSPs appears to be unknown, although it has been postulated that expression of a particular VSP might influence the relative ability of Giardia trophozoites to colonise a particular species of host [26]. Giardia trophozoites genetically engineered to express “numerous” VSPs simultaneously can act as a vaccine (whether given as live organisms, or as an inanimate mixture of antigens) to generate protective anti-Giardia immunity in a gerbil host [24]. The implications of this finding for understanding the “normal” mechanism(s) of host protective immunity against Giardia infection(s) are, however, unclear.

Sera from G. intestinalis-infected human subjects contain antibodies directed against trophozoite VSPs [23]. Of possibly greater biological significance, antibodies against G. intestinalis trophozoite proteins that are structurally conserved (invariant) have also been identified in sera from Giardia-infected individuals. Trophozoite invariant proteins recognised by human serum antibodies include α-giardins (a group of proteins originally regarded as “internal” in trophozoite adhesive discs, though later identified on trophozoite surface membranes and flagella) [22, 33–35], fructose-1,6-bisphosphate aldolase, and G. intestinalis enzymes involved in arginine metabolism (arginine deiminase and ornithine carbamoyl transferase) [21]. Host immunological memory is suggested by the isolation of Giardia-reactive CD4+ T lymphocytes from the peripheral blood of human subjects known to have been infected with G. intestinalis during an outbreak of giardiasis 5 years previously [7]. One can speculate that these CD4+ T lymphocytes included cells that were able to provide “help” for Giardia-specific antibody production by B lymphocytes.

A plausible mechanism for presumed antibody-mediated clearance of Giardia infections would involve prevention (by antibodies) of trophozoite attachment to the host intestinal epithelium [8] followed by peristaltic expulsion of these organisms from the intestine. Reportedly, an antibody against δ-giardin (a protein in trophozoite adhesive discs) inhibits G. intestinalis trophozoite attachment to non-biological surfaces; however, the pertinent antibody may (also) have killed trophozoites, as judged by their morphology after exposure to the antibody [12]. Oral administration of a Salmonella enterica strain bioengineered to express G. intestinalis α-1 giardin induced serum IgG and intestinal IgA antibodies against α-1 giardin in mice, and conferred some protection against subsequent G. intestinalis infection in the animals [11]. Although recombinant α-1 giardin of G. intestinalis binds to human intestinal epithelial cells in vitro [34], exposure of G. intestinalis trophozoites to antibody directed against α-1 giardin did not inhibit the ability of these organisms to become attached to a non-biological surface [6]. Further work may be needed to clarify the role, if any, of antibodies against giardin(s) in clearance of/protection against Giardia infections.

Experimental work with mice has suggested that T lymphocytes can contribute directly (i.e., in the absence of antibodies) to clearance of infection with a clone of G. intestinalis (GS/M-H7) [27]. The mechanism(s) involved in this putative T-cell-mediated clearance of Giardia infection does not appear to be known (it may be worth mentioning that a postulated effector role for T cells in the clearance process would not be identical to CD4+ T-cell-mediated help for anti-Giardia antibody production) [27].

Studies of Giardia infections in rodents have implicated interleukin-6 (IL-6) in anti-Giardia immunity. IL-6-deficient mice have a diminished ability to clear infection caused by G. intestinalis [2, 36]. The mice studied in the pertinent experiments were able to produce intestinal anti-trophozoite IgA; the findings suggest that IL-6 contributes to clearance of Giardia infection in mice (albeit by an unknown mechanism that appears not to involve IgA). Recent work has identified dendritic cells (of bone marrow origin) as a source of IL-6 that promotes clearance of G. intestinalis infection in mice [13].

There is evidence that intestinal nitric oxide (NO) contributes to host clearance of Giardia trophozoites [5]. In view of the fact that arginine is a substrate for generation of NO, it is interesting that Giardia trophozoites appear to compete with the host for arginine [5]. Giardia trophozoites are able to metabolise arginine [25]. Uptake and metabolism of arginine by Giardia trophozoites has implications for host nutrition (reducing the proportion of dietary arginine available for absorption by the host), as well as for trophozoite survival via reduced availability of arginine for host NO production [29, 30].

Experimental work has implicated mast cells in clearance of Giardia infections, at least in mice [16]. There is evidence of increased expression of mast cell protease genes during Giardia infections in mice [31], though whether this increased gene expression contributes to a possible role for mast cells in promoting intestinal peristalsis (and consequent expulsion of Giardia trophozoites from the intestinal lumen) is unclear [16].

As mentioned above, mice can be partially protected against Giardia infection, by oral administration of bacteria that have been genetically engineered to express Giardia proteins [11, 15]. There would seem to be little clinical imperative to try to develop a vaccine against human giardiasis, even if doing so were eventually found to be technically feasible.

Author’s Disclaimer: The content of this article does not necessarily reflect the views of the US Department of Veterans Affairs or of the US Government.

Acknowledgments

The author is grateful to the staff of the Medical Library, Department of Veterans Affairs Medical Center, Philadelphia, for obtaining online copies of publications.

References

  1. Belosevic M, Faubert GM, Dharampaul S. 1994. Antimicrobial action of antibodies against Giardia muris trophozoites. Clinical and Experimental Immunology, 95, 485–489. [CrossRef] [PubMed] [Google Scholar]
  2. Bienz M, Dai WJ, Welle M, Gottstein B, Mȕller N. 2003. Interleukin-6-deficient mice are highly susceptible to Giardia lamblia infections but exhibit normal intestinal immunoglobulin A responses against the parasite. Infection and Immunity, 71, 1569–1573. [CrossRef] [PubMed] [Google Scholar]
  3. Butscher WG, Faubert GM. 1988. The therapeutic action of monoclonal antibodies against a surface glycoprotein of Giardia muris. Immunology, 64, 175–180. [PubMed] [Google Scholar]
  4. Eckmann L. 2003. Mucosal defences against Giardia. Parasite Immunology, 25, 259–270. [CrossRef] [PubMed] [Google Scholar]
  5. Eckmann L, Laurent F, Langford TD, Hetsko ML, Smith JR, Kagnoff MF, Gillin FD. 2000. Nitric oxide production by human intestinal epithelial cells and competition for arginine as potential determinants of host defense against the lumen-dwelling pathogen Giardia lamblia. Journal of Immunology, 164, 1478–1487. [CrossRef] [Google Scholar]
  6. Feliziani C, Merino MC, Rivero MR, Hellman U, Pistoresi-Palencia MC, Rópolo AS. 2011. Immunodominant proteins α-1 giardin and β-giardin are expressed in both assemblages A and B of Giardia lamblia. BMC Microbiology, 11, 233. [CrossRef] [PubMed] [Google Scholar]
  7. Hanevik K, Kristofferson E, Svard S, Bruserud O, Ringqvist E, Sørnes S, Langeland N. 2011. Human cellular immune response against Giardia lamblia 5 years after acute giardiasis. Journal of Infectious Diseases, 204, 1779–1786. [CrossRef] [Google Scholar]
  8. Hernández-Sánchez J, Liñan RF, M del R Salinas-Tobón, Ortega-Pierres G. 2008. Giardia duodenalis: Adhesion-deficient clones have reduced ability to establish infection in Mongolian gerbils. Experimental Parasitology, 119, 364–372. [CrossRef] [PubMed] [Google Scholar]
  9. Heyworth MF, Carlson JR, Ermak TH. 1987. Clearance of Giardia muris infection requires helper/inducer T lymphocytes. Journal of Experimental Medicine, 165, 1743–1748. [CrossRef] [Google Scholar]
  10. Heyworth MF, Vergara JA. 1994. Giardia muris trophozoite antigenic targets for mouse intestinal IgA antibody. Journal of Infectious Diseases, 169, 395–398. [CrossRef] [Google Scholar]
  11. Jenikova G, Hruz P, Andersson MK, Tejman-Yarden N, Ferreira PCD, Andersen YS, Davids BJ, Gillin FD, Svärd SG, Curtiss R III, Eckmann L. 2011. α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. Vaccine, 29, 9529–9537. [CrossRef] [PubMed] [Google Scholar]
  12. Jenkins MC, O’Brien CN, Murphy C, Schwarz R, Miska K, Rosenthal B, Trout JM. 2009. Antibodies to the ventral disc protein δ-giardin prevent in vitro binding of Giardia lamblia trophozoites. Journal of Parasitology, 95, 895–899. [CrossRef] [Google Scholar]
  13. Kamda JD, Nash TE, Singer SM. 2012. Giardia duodenalis: Dendritic cell defects in IL-6 deficient mice contribute to susceptibility to intestinal infection. Experimental Parasitology, 130, 288–291. [CrossRef] [PubMed] [Google Scholar]
  14. Langford TD, Housley MP, Boes M, Chen J, Kagnoff MF, Gillin FD, Eckmann L. 2002. Central importance of immunoglobulin A in host defense against Giardia spp. Infection and Immunity, 70, 11–18. [CrossRef] [PubMed] [Google Scholar]
  15. Lee P, Abdul-Wahid A, Faubert GM. 2009. Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii. Microbes and Infection, 11, 20–28. [CrossRef] [Google Scholar]
  16. Li E, Zhao A, Shea-Donohue T, Singer SM. 2007. Mast cell-mediated changes in smooth muscle contractility during mouse giardiasis. Infection and Immunity, 75, 4514–4518. [CrossRef] [PubMed] [Google Scholar]
  17. Nash TE. 1997. Antigenic variation in Giardia lamblia and the host’s immune response. Philosophical Transactions of the Royal Society of London B, 352, 1369–1375. [CrossRef] [Google Scholar]
  18. Nash TE. 2002. Surface antigenic variation in Giardia lamblia. Molecular Microbiology, 45, 585–590. [CrossRef] [PubMed] [Google Scholar]
  19. O’Handley RM, Ceri H, Anette C, Olson ME. 2003. Passive immunity and serological immune response in dairy calves associated with natural Giardia duodenalis infections. Veterinary Parasitology, 113, 89–98. [CrossRef] [PubMed] [Google Scholar]
  20. Olmez S, Aslan M, Yavuz A, Bulut G, Dulger AC. 2014. Diffuse nodular lymphoid hyperplasia of the small bowel associated with common variable immunodeficiency and giardiasis: a rare case report. Wiener klinische Wochenschrift, 126, 294–297. [CrossRef] [PubMed] [Google Scholar]
  21. Palm JED, Weiland ME-L, Griffiths WJ, Ljungström I, Svärd SG. 2003. Identification of immunoreactive proteins during acute human giardiasis. Journal of Infectious Diseases, 187, 1849–1859. [CrossRef] [Google Scholar]
  22. Peattie DA, Alonso RA, Hein A, Caulfield JP. 1989. Ultrastructural localization of giardins to the edges of disk microribbons of Giardia lamblia and the nucleotide and deduced protein sequence of alpha giardin. Journal of Cell Biology, 109, 2323–2335. [CrossRef] [Google Scholar]
  23. Priest JW, Moss DM, Visvesvara GS, Jones CC, Li A, Isaac-Renton JL. 2010. Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvum antigens. Clinical and Vaccine Immunology, 17, 1695–1707. [CrossRef] [Google Scholar]
  24. Rivero FD, Saura A, Prucca CG, Carranza PG, Torri A, Lujan HD. 2010. Disruption of antigenic variation is crucial for effective parasite vaccine. Nature Medicine, 16, 551–557. [CrossRef] [PubMed] [Google Scholar]
  25. Schofield PJ, Edwards MR, Matthews J, Wilson JR. 1992. The pathway of arginine catabolism in Giardia intestinalis. Molecular and Biochemical Parasitology, 51, 29–36. [CrossRef] [PubMed] [Google Scholar]
  26. Singer SM, Elmendorf HG, Conrad JT, Nash TE. 2001. Biological selection of variant-specific surface proteins in Giardia lamblia. Journal of Infectious Diseases, 183, 119–124. [CrossRef] [Google Scholar]
  27. Singer SM, Nash TE. 2000. T-cell-dependent control of acute Giardia lamblia infections in mice. Infection and Immunity, 68, 170–175. [CrossRef] [PubMed] [Google Scholar]
  28. Smith PD, Gillin FD, Brown WR, Nash TE. 1981. IgG antibody to Giardia lamblia detected by enzyme-linked immunosorbent assay. Gastroenterology, 80, 1476–1480. [PubMed] [Google Scholar]
  29. Stadelmann B, Hanevik K, Andersson MK, Bruserud O, Svärd SG. 2013. The role of arginine and arginine-metabolizing enzymes during Giardia-host cell interactions in vitro. BMC Microbiology, 13, 256. [CrossRef] [PubMed] [Google Scholar]
  30. Stadelmann B, Merino MC, Persson L, Svärd SG. 2012. Arginine consumption by the intestinal parasite Giardia intestinalis reduces proliferation of intestinal epithelial cells. PLoS ONE, 7(9), e45325. [CrossRef] [PubMed] [Google Scholar]
  31. Tako EA, Hassimi MF, Li E, Singer SM. 2013. Transcriptomic analysis of the host response to Giardia duodenalis infection reveals redundant mechanisms for parasite control. mBio, 4(6), e00660-13. [PubMed] [Google Scholar]
  32. Téllez A, Palm D, Weiland M, Alemán J, Winiecka-Krusnell J, Linder E, Svärd S. 2005. Secretory antibodies against Giardia intestinalis in lactating Nicaraguan women. Parasite Immunology, 27, 163–169. [CrossRef] [PubMed] [Google Scholar]
  33. Weiland ME-L, McArthur AG, Morrison HG, Sogin ML, Svärd SG. 2005. Annexin-like alpha giardins: a new cytoskeletal gene family in Giardia lamblia. International Journal for Parasitology, 35, 617–626. [CrossRef] [PubMed] [Google Scholar]
  34. Weiland ME-L, Palm JED, Griffiths WJ, McCaffery JM, Svärd SG. 2003. Characterisation of alpha-1 giardin: an immunodominant Giardia lamblia annexin with glycosaminoglycan-binding activity. International Journal for Parasitology, 33, 1341–1351. [CrossRef] [PubMed] [Google Scholar]
  35. Wenman WM, Meuser RU, Nyugen Q, Kilani RT, El-Shewy K, Sherburne R. 1993. Characterization of an immunodominant Giardia lamblia protein antigen related to alpha giardin. Parasitology Research, 79, 587–592. [CrossRef] [PubMed] [Google Scholar]
  36. Zhou P, Li E, Zhu N, Robertson J, Nash T, Singer SM. 2003. Role of interleukin-6 in the control of acute and chronic Giardia lamblia infections in mice. Infection and Immunity, 71, 1566–1568. [CrossRef] [PubMed] [Google Scholar]

Cite this article as: Heyworth MF: Immunological aspects of Giardia infections. Parasite, 2014, 21, 55.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.